Drug intelligence / Profile preview

adefovir dipivoxil (Akron Molecules AG)

Development stage: Approved
Lead developer: Akron Molecules
Modality: Small Molecules
Administration: Oral

Overview

Adefovir dipivoxil (code name AKR-202) is an oral small molecule drug developed by Akron Molecules AG. It has been investigated primarily for the treatment of moderate to severe osteoarthritis pain in the knee. The drug acts as a purinoceptor modulator, though its established mechanism in other indications is as a nucleotide analog reverse transcriptase inhibitor. In this context, it was evaluated for analgesic and anti-inflammatory effects related to osteoarthritis[1][2][3].

Brand names: Hepsera
Other names: AKR 202AKR202AKR-202

Targets

HBV Pol (Hepatitis B virus polymerase)POLA1 (DNA polymerase alpha)POLG (Mitochondrial DNA polymerase gamma)

Beyond the preview

Go deeper on adefovir dipivoxil (Akron Molecules AG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adefovir dipivoxil (Akron Molecules AG).

Explore the full profile